IRIS
ASCIERTO, PAOLO ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.430
NA - Nord America 3.939
EU - Europa 1.929
SA - Sud America 325
AF - Africa 153
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.790
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.870
US - Stati Uniti d'America 3.750
CN - Cina 1.069
VN - Vietnam 940
JP - Giappone 629
FR - Francia 591
RU - Federazione Russa 369
IT - Italia 362
HK - Hong Kong 299
BR - Brasile 220
DE - Germania 162
IN - India 161
IQ - Iraq 88
NL - Olanda 86
GB - Regno Unito 81
MX - Messico 74
CA - Canada 72
UA - Ucraina 59
PH - Filippine 47
BD - Bangladesh 39
FI - Finlandia 36
TH - Thailandia 36
ZA - Sudafrica 32
AR - Argentina 31
KR - Corea 30
ES - Italia 27
PK - Pakistan 24
EG - Egitto 23
ID - Indonesia 20
PL - Polonia 18
EC - Ecuador 17
TR - Turchia 17
IE - Irlanda 16
JO - Giordania 16
MY - Malesia 16
VE - Venezuela 16
CH - Svizzera 14
KE - Kenya 14
SE - Svezia 14
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PY - Paraguay 11
TW - Taiwan 11
AZ - Azerbaigian 10
CI - Costa d'Avorio 10
SA - Arabia Saudita 10
TN - Tunisia 10
DZ - Algeria 9
BG - Bulgaria 8
CO - Colombia 8
IL - Israele 8
MA - Marocco 8
AL - Albania 7
BO - Bolivia 7
CL - Cile 7
JM - Giamaica 7
LB - Libano 7
AT - Austria 6
DO - Repubblica Dominicana 6
EE - Estonia 6
NG - Nigeria 6
RS - Serbia 6
AM - Armenia 5
BE - Belgio 5
BY - Bielorussia 5
CZ - Repubblica Ceca 5
LT - Lituania 5
PA - Panama 5
PS - Palestinian Territory 5
PT - Portogallo 5
CY - Cipro 4
GT - Guatemala 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LV - Lettonia 4
PE - Perù 4
RO - Romania 4
SY - Repubblica araba siriana 4
AD - Andorra 3
AU - Australia 3
BH - Bahrain 3
CR - Costa Rica 3
ET - Etiopia 3
GA - Gabon 3
GR - Grecia 3
IR - Iran 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TG - Togo 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
CM - Camerun 2
CW - ???statistics.table.value.countryCode.CW??? 2
GF - Guiana Francese 2
Totale 13.716
Salva come PNG Salva come JPEG
Città #
San Jose 2.143
Singapore 1.470
Tokyo 616
Lauterbourg 521
Ashburn 404
Hong Kong 271
Ho Chi Minh City 266
Hanoi 211
Beijing 145
Naples 92
Moscow 85
Los Angeles 83
Hefei 74
New York 71
Amsterdam 68
Santa Clara 67
Council Bluffs 63
Chandler 47
Mexico City 44
Da Nang 40
Frankfurt am Main 39
Haiphong 38
Baghdad 37
Dallas 37
Orem 33
São Paulo 33
Chicago 31
Munich 30
Buffalo 27
Montreal 26
Rome 24
The Dalles 24
Milan 22
Jacksonville 21
Shanghai 19
Toronto 19
Bangkok 18
Boston 18
Johannesburg 16
Millbury 16
Napoli 16
Mumbai 15
Amman 14
Cairo 14
Denver 14
Hải Dương 14
Nairobi 14
Redondo Beach 14
Seoul 14
Biên Hòa 13
Seattle 13
Warsaw 13
Boardman 12
Brooklyn 12
Des Moines 11
Lahore 11
London 11
Nanjing 11
Princeton 11
Stockholm 11
Tashkent 11
Turku 11
Wilmington 11
Ann Arbor 10
Casandrino 10
Chennai 10
Nuremberg 10
Phoenix 10
Woodbridge 10
Atlanta 9
Guangzhou 9
Kuala Lumpur 9
Poplar 9
Can Tho 8
Helsinki 8
Quảng Ngãi 8
Thái Bình 8
Baku 7
Cape Town 7
Houston 7
Hưng Yên 7
Manchester 7
Miami 7
New Delhi 7
Pune 7
Quận Ba 7
Ankara 6
Asunción 6
Bắc Giang 6
Chengdu 6
Erbil 6
Falkenstein 6
Hangzhou 6
Kochi 6
Lappeenranta 6
Nasiriyah 6
Nha Trang 6
Panama City 6
Salt Lake City 6
Shenyang 6
Totale 7.875
Salva come PNG Salva come JPEG
Nome #
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up 256
Integrated genomics identifies MiR-181/TFAM pathway as a critical driver of drug resistance in melanoma 210
Innate Immune Cells in Melanoma: Implications for Immunotherapy 180
FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy 175
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 162
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): A population-based study 160
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 140
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 139
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 134
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab 132
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents 130
Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma 118
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? 111
Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes’ iTNF-α expression 111
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies 111
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 106
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells 104
Severe protracted intestinal cryptosporidiosis associated with interferon g deficiency: pediatric case report. 104
Nemo binding domain peptide could induce apoptosis in several melanoma cell lines 104
NEMO-binding domain peptide induces apoptosis of human melanoma cells through inhibition of constitutive NF-kB activation 103
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps 99
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 91
HHV-8 prevalence, immunosuppression and Kaposi’s sarcoma in South Italy 86
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 69
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. 68
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma 62
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 57
Expression of the anti-apoptotic protein BAG3 in human melanomas. 55
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: A retropective study 55
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial 48
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 46
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma 45
Prognostic value of serum VEGF in melanoma patients: a pilot study 44
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma 43
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 43
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301 42
The role of BRAF V600 mutation in melanoma 40
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 40
Where Reflectance Confocal Microscopy Provides the Greatest Benefit for Diagnosing Skin Cancers: The Experience of the National Cancer Institute of Naples 39
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 39
Defining the critical hurdles in cancer immunotherapy 39
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab 39
When rarity meets thoracic cancers: a narrative review from ITMIG 2024 38
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 38
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial 38
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study 37
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 37
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma 37
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 36
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 36
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial 36
Emerging therapeutics for melanoma 36
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma 36
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) 35
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 35
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 35
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 35
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma 34
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma 34
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy 34
Melanoma pathophysiology and drug targets 34
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations 34
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma 34
Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 34
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery 33
Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma 33
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis 33
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for 33
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP) 32
Clinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational Study 32
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy 32
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy 32
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018) 32
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma 32
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial 31
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies 31
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors 31
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts 31
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, 10.1038/s41591-023-02583-2) 31
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients 31
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort 31
Combination therapy: the next opportunity and challenge of medicine 30
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 30
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial 30
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations 30
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma 30
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma 30
Use of artificial intelligence chatbots in clinical management of immune-related adverse events 30
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors 30
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 29
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial (vol 5, pg 187, 2018) 29
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients 29
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations 29
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma 28
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters 28
Development of muscle spasm during Vismodegib treatment and the effect of treatment interruptions: exploratory analyses from the STEVIE study 28
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma 28
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma 28
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer 27
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (vol 378, pg 1976, 2018) 27
Totale 5.853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.394
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.394
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 3 7 4
2021/2022217 0 4 0 1 1 3 4 15 131 9 14 35
2022/2023127 16 5 3 6 19 10 0 12 13 20 7 16
2023/2024146 10 19 24 16 6 11 2 17 2 2 22 15
2024/2025919 46 38 11 17 36 60 93 56 84 93 303 82
2025/202612.902 181 163 235 717 2.941 1.232 1.808 2.333 2.390 902 0 0
Totale 14.492